-
Share
673 Posts.
321
16/09/20
17:02
Share
Hi Mark,
No doubt Australian investors generally struggle to look outside our own backyard, and appropriately value the global potential.
Also worth having a look at Dexcom (DXCM on the Nasdaq) - circa $40 billion USD market cap, on about $1.5bn USD revenue in 2019.
They have done for diabetes what Respiri is attempting to do for asthma.
It is those that can see the bigger picture that will make the big $$ with this stock IMO.
-
